

ImmuPharma PLC
("ImmuPharma" or the "Company")

Notification of Change of AGM Venue

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that the Company's Annual General Meeting (AGM) confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU.

The COVID-19 Guidance rules still apply, as set out in the announcement issued on 21 May 2020, (see Notes to Editors). Any shareholders attempting to gain access to the AGM will be excluded from the meeting on the ground of public safety.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 ("MAR").

For further information please contact:

ImmuPharma PLC (www.immupharma.com)	+ 44 (0) 207 152 4080
Tim McCarthy, Chairman	
Dimitri Dimitriou, Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)	+44 (0) 203 368 8974
Neil Baldwin	
Stanford Capital Partners (Joint Broker)	+44 (0) 203 815 8880
Patrick Claridge, John Howes	
SI Capital (Joint Broker)	+44 (0) 1483 413500
Nick Emerson	
4Reliance (Euronext Growth Listing Sponsor)	+32 (0) 2 747 02 60
Jean-Charles Snoy	
Degroof Petercam (Liquidity Provider)	+32 (0) 2 287 95 34
Erik De Clippel	
Backstage Communication	
Olivier Duquaine	+32 (0) 477 504 784
Gunther De Backer	+32 (0) 475 903 909

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. For additional information about ImmuPharma please visit www.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHC7VUS895.

COVID-19 Guidance

We note the current issues surrounding COVID-19 (coronavirus) and the rapidly developing public health guidance in the UK at the time of writing. This includes the stringent requirements announced on 23 March 2020, which require UK nationals to stay at home except in tightly defined circumstances (which do not include attending an AGM), the social distancing and shielding guidance for those over the age of 70 or with underlying medical conditions, and the ban on all non-essential travel. The health and safety of our shareholders and colleagues is always our utmost priority.

As it is no longer possible to hold the AGM in the way that the Board had planned, we cannot allow shareholders to attend in person. Any shareholders attempting to gain access to the AGM will be excluded from the meeting on grounds of public safety. In the light of the above, we strongly encourage you to consider ensuring your vote is counted by submission of the proxy by post as detailed in the Notice of Annual General Meeting.